Skip to Content

Purixan Approval History

FDA Approved: Yes (First approved April 28, 2014)
Brand name: Purixan
Generic name: mercaptopurine
Dosage form: Oral Suspension
Company: Nova Laboratories, Ltd.
Treatment for: Acute Lymphoblastic Leukemia

Purixan (mercaptopurine) is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia.

Development History and FDA Approval Process for Purixan

DateArticle
Apr 29, 2014Approval FDA Approves Purixan (mercaptopurine) Oral Suspension

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide